Valeant Canada Ltd., a prominent player in the pharmaceutical and biotechnology industry, is headquartered in Canada. Founded in 1960, the company has established itself as a leader in specialty pharmaceuticals, focusing on dermatology, ophthalmology, and neurology. With a strong presence in North America and expanding operations in international markets, Valeant is known for its innovative approach to drug development and patient care. The company’s core products include a diverse range of prescription medications and over-the-counter treatments, distinguished by their efficacy and unique formulations. Valeant's commitment to research and development has led to significant milestones, including strategic acquisitions that enhance its product portfolio. Recognised for its market resilience, Valeant Canada Ltd. continues to make strides in improving health outcomes while maintaining a strong competitive position in the global pharmaceutical landscape.
How does Valeant Canada Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Valeant Canada Ltd.'s score of 40 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Valeant Canada Ltd., headquartered in Canada, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Bausch Health Companies Inc., which means that any emissions data or climate commitments would be inherited from this parent organization. As part of its climate strategy, Bausch Health Companies Inc. has set various reduction initiatives, although specific targets for Valeant Canada Ltd. are not detailed. The company is involved in broader sustainability efforts, including participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are cascaded from Bausch Health Companies Inc. at a corporate family level. While Valeant Canada Ltd. does not currently report its own emissions figures, it is important to note that the company is aligned with the climate commitments and reduction strategies of its parent organization, Bausch Health Companies Inc. This alignment indicates a commitment to addressing climate change and reducing carbon footprints in line with industry standards.
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 46,686,000 | 00,000,000 |
| Scope 2 | 50,513,000 | 00,000,000 |
| Scope 3 | 19,260,000 | 00,000,000 |
Valeant Canada Ltd.'s Scope 3 emissions, which increased by 41% last year and increased by approximately 41% since 2022, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 21% of total emissions under the GHG Protocol, with "Waste Generated in Operations" representing nearly all of their reported Scope 3 footprint.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Valeant Canada Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.